Enliven Therapeutics, Inc.
ELVN
$27.25
-$0.54-1.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.04M | 6.87M | 7.09M | 6.80M | 6.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.29M | 25.10M | 28.58M | 31.69M | 26.90M |
| Operating Income | -34.29M | -25.10M | -28.58M | -31.69M | -26.90M |
| Income Before Tax | -29.67M | -20.15M | -25.34M | -28.54M | -23.18M |
| Income Tax Expenses | -- | -- | -- | -- | 0.00 |
| Earnings from Continuing Operations | -29.67M | -20.15M | -25.34M | -28.54M | -23.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.67M | -20.15M | -25.34M | -28.54M | -23.18M |
| EBIT | -34.29M | -25.10M | -28.58M | -31.69M | -26.90M |
| EBITDA | -34.24M | -25.03M | -28.50M | -31.62M | -26.82M |
| EPS Basic | -0.48 | -0.32 | -0.49 | -0.57 | -0.46 |
| Normalized Basic EPS | -0.30 | -0.20 | -0.30 | -0.36 | -0.29 |
| EPS Diluted | -0.48 | -0.32 | -0.49 | -0.57 | -0.46 |
| Normalized Diluted EPS | -0.30 | -0.20 | -0.30 | -0.36 | -0.29 |
| Average Basic Shares Outstanding | 62.21M | 62.09M | 52.11M | 50.05M | 49.86M |
| Average Diluted Shares Outstanding | 62.21M | 62.09M | 52.11M | 50.05M | 49.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |